|
18 Sep 2025 |
Emami
|
Consensus Share Price Target
|
603.25 |
710.46 |
- |
17.77 |
buy
|
|
|
|
|
26 May 2015
|
Emami
|
HDFC Securities
|
603.25
|
|
1035.40
(-41.74%)
|
Pre-Bonus/ Split |
Buy
|
|
|
Buy on dips to Rs 842 - Rs 872 for Target of Rs 962 in 1 quarter
|
|
15 May 2015
|
Emami
|
Phillip Capital
|
603.25
|
990.00
|
1032.65
(-41.58%)
|
Pre-Bonus/ Split |
Neutral
|
|
|
growth across categories and contribution from new product launches. New launches contributed 8% to top line growth as compared to 5% in Q3FY15. For FY15 new product launches contributed around 6% of revenues and the management expects similar...
|
|
14 May 2015
|
Emami
|
Chola Wealth Direct
|
603.25
|
964.00
|
1016.10
(-40.63%)
|
Pre-Bonus/ Split |
Neutral
|
|
|
Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales and PAT have grown at a CAGR of 18.4% and 23.2% respectively (FY08-13). Geographical breakup of sales: North (29%), West (27%), South (23%) and East (21%). Export contributes ~10.4% of total revenue. Company...
|
|
16 Feb 2015
|
Emami
|
HDFC Securities
|
603.25
|
|
1028.40
(-41.34%)
|
Pre-Bonus/ Split |
Buy
|
|
|
Buy on dips to Rs 842 - Rs 872 for Target of Rs 962 in 1 quarter
|
|
30 Jan 2015
|
Emami
|
Chola Wealth Direct
|
603.25
|
887.00
|
919.25
(-34.38%)
|
Pre-Bonus/ Split |
Neutral
|
|
|
Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales and PAT have grown at a CAGR of 18.4% and 23.2% respectively (FY08-13). Geographical breakup of sales: North (29%), West (27%), South (23%) and East (21%). Export contributes ~10.4% of total revenue. Company...
|
|
31 Dec 2014
|
Emami
|
Ashika Research
|
603.25
|
924.00
|
786.00
(-23.25%)
|
Target met |
Buy
|
|
|
Emami Ltd, the flagship company of the Group, is one of the leading and fastest growing personal and healthcare businesses in India, with an enviable portfolio of household brand names...
|
|
01 Jul 2014
|
Emami
|
GEPL Capital
|
603.25
|
667.00
|
510.65
(18.13%)
|
Target met |
Buy
|
|
|
company's strategy to expand into the male grooming segment. In the `21,000 mn market, Emami has entered the deodorant markets with brand HE Emami plans to be a `2,000 mn brand in two years since launch. So by FY17 they expect to...
|
|
22 May 2012
|
Emami
|
Ashika Research
|
603.25
|
535.00
|
307.84
(95.97%)
|
Target met |
Buy
|
|
|
Emami Ltd, the flagship company of Emami Group, is a leading player in the personal and healthcare consumer products industry in India. The company has over 30 brands under their portfolio. It has developed popular brands like...
|